InspireMD (NYSE:NSPR) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of InspireMD (NYSE:NSPRFree Report) in a research report report published on Tuesday morning. The brokerage issued a sell rating on the stock.

Separately, Piper Sandler reissued an overweight rating and set a $4.50 target price on shares of InspireMD in a research report on Tuesday, September 17th.

Check Out Our Latest Report on InspireMD

InspireMD Trading Up 3.5 %

Shares of NSPR opened at $2.69 on Tuesday. The stock has a 50 day moving average of $2.82 and a 200 day moving average of $2.52. The company has a market capitalization of $67.06 million, a price-to-earnings ratio of -3.49 and a beta of 0.90. InspireMD has a 12 month low of $1.81 and a 12 month high of $3.85.

InspireMD (NYSE:NSPRGet Free Report) last released its earnings results on Tuesday, August 6th. The company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.03). The business had revenue of $1.74 million for the quarter, compared to the consensus estimate of $1.74 million. InspireMD had a negative return on equity of 62.02% and a negative net margin of 388.67%. During the same quarter in the previous year, the firm earned ($0.24) earnings per share. As a group, equities research analysts predict that InspireMD will post -0.82 earnings per share for the current year.

Institutional Trading of InspireMD

An institutional investor recently bought a new position in InspireMD stock. Mesirow Financial Investment Management Inc. acquired a new position in InspireMD, Inc. (NYSE:NSPRFree Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 30,000 shares of the company’s stock, valued at approximately $71,000. Mesirow Financial Investment Management Inc. owned about 0.13% of InspireMD as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 44.78% of the company’s stock.

InspireMD Company Profile

(Get Free Report)

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.

Featured Stories

Receive News & Ratings for InspireMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InspireMD and related companies with MarketBeat.com's FREE daily email newsletter.